Unprecedented Results Compared With Current Standard of Care

BETHESDA, Md., April 18, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today that Brad Silver, an All American swimming
and water polo athlete who was diagnosed with Glioblastoma
multiforme (GBM) brain cancer in late 2002, and was treated with
DCVax-L in March of 2003, just celebrated the 10th anniversary of
his continued cancer-free survival.

GBM is the most aggressive and lethal form of brain cancer.
 With today’s standard of care (surgery, 6 weeks of daily
radiation to the brain plus daily chemotherapy, followed by monthly
chemotherapy), this cancer typically recurs within 7 months and
kills within 14.6 months.  Without all these treatments, GBM
typically kills within months of diagnosis.

When Brad was diagnosed, he was told by his doctors that he had
only about 2 months to live.

Brad is now the second patient from the Phase I/II trials with
DCVax-L for GBM who has surpassed the 10-year cancer-free survival
mark.  The first such patient has further passed the 11-year
cancer-free mark. 

Beyond these two 10-plus year survivors, the long-term follow-up
data on the other patients from the Phase I/II trials shows a “long
tail” of survival among them.  The median survival of GBM
patients treated with DCVax-L was 3 years (in contrast to only 14.6
months median survival with standard of care).  The “long
tail” also stretched significantly further, beyond this
median:  33% of the patients reached or exceeded 4 years of
survival, and 27% of the patients reached or exceeded 6 years of
survival (in contrast, only 3% or so of GBM patients are still
alive at the 5-year mark with standard of care treatments). 
Several of these patients are continuing to move through further
years of survival.

“When I was told I had several months left to live in 2002, with
my wife several months pregnant, I was determined to find a
clinical trial that would allow me to see and raise my son,”
commented Brad Silver.  “When that quest led me to DCVax and
Dr. Linda Liau at UCLA, the natural renewal of my own immune system
made more sense to me than just a continuation of the system-wide
poisoning of chemotherapy.  And it worked.  Not only did
the tumor disappear and stay away for all this time, but the only
side effect I had was unbridled happiness and a new freedom. 
My son Brad II, who was born 10 days after my first DCVax
treatment, will be 10 years old next week, and today I am there for
my family thanks to DCVax.”

Brad is not just in continuing remission, he is also a very
hardy physical specimen. While he was a long-time resident of Ohio,
Brad coached women’s water polo at an NCAA division II College in
Ohio. He is currently living abroad with his wife on a project
assignment, and teaches swimming, physical education and sailing,
and guides kayak tours.  For fun he is an avid
surfer.  

Brad tells his inspiring story in his own words in an interview
last year, with a short excerpt on YouTube at
http://www.youtube.com/user/NWBioNWBO/featured.

NW Bio is currently conducting a 312-patient Phase III, double
blind, randomized, placebo- controlled clinical trial with DCVax-L
for GBM brain cancer using the same DCVax-L vaccine that Brad
Silver received.  This trial currently has 44 active sites
across the US, and nearly 30 additional sites in varying states of
preparation in Europe.

“We are thrilled to see Brad become our second GBM patient to
pass the 10-year cancer-free milestone after treatment with
DCVax-L,” commented Linda F. Powers, CEO of NW Bio.  “With
‘state of the art’ treatments today, 10-year survival in GBM is
unheard of.  Indeed, even survival half that long is virtually
unheard of.  The “long tail” of survival among a large
percentage of our patients is a particularly compelling aspect of
our DCVax technology.”

“Our hat is off to Brad and his family for their courage and
trail blazing role in helping demonstrate the potential of DCVax-L
for more patients in the future,” Ms. Powers continued.  
“Brad’s example reinforces our own determination to bring DCVax to
other patients as soon as possible.” 

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
United States and Europe.  The Company has a broad platform
technology for DCVax dendritic cell-based vaccines.  The
Company’s lead program is a 312-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM).  GBM is the most
aggressive and lethal form of brain cancer.  The Company also
previously received clearance from the FDA for a 612-patient Phase
III trial in prostate cancer, and clearance from the FDA for Phase
I/II trials in multiple other cancers.  The Company also
conducted a Phase I/II trial with DCVax for metastatic ovarian
cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995.  Words such as “expect,” “believe,”
“intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and
similar expressions are intended to identify forward-looking
statements.  Actual results may differ materially from those
projected in any forward-looking statement.  Specifically,
there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the
Company’s ability to raise additional capital, risks related to the
Company’s ability to enroll patients in its clinical trials and
complete the trials on a timely basis, the uncertainty of the
clinical trials process, uncertainties about the timely performance
of third parties, and whether the Company’s products will
demonstrate safety and efficacy.  Additional information on
these and other factors, including Risk Factors, which could affect
the Company’s results, is included in its Securities and Exchange
Commission (“SEC”) filings.  Finally, there may be other
factors not mentioned above or included in the Company’s SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement.  You should
not place undue reliance on any forward-looking statements. 
The Company assumes no obligation to update any forward-looking
statements as a result of new information, future events or
developments, except as required by securities laws.